Neurocrine registers Phase 2a trial of NBI-1117567 in mild to moderate Alzheimer's disease
A new record posted September 22, 2026 lists a placebo-controlled study of NBI-1117567 added on top of standard acetylcholinesterase inhibitor therapy.
Neurocrine Biosciences had one new trial registration posted this week.
- NBI-1117567, an oral drug taken once daily, is set for a Phase 2a, multicenter, randomized, placebo-controlled study evaluating efficacy, safety, tolerability and pharmacokinetics in adults with mild to moderate Alzheimer's disease who are receiving stable treatment with an acetylcholinesterase inhibitor.1 The study is not yet recruiting, with an estimated start in October 2026 and estimated primary completion in May 2028.1 It plans to enroll 135 participants across low dose, high dose, and placebo arms.1 The primary outcome is change from baseline in Neuropsychological Test Battery (NTB) Composite Score at Day 85.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.